SRV2 Antibody

What is SRV2/Srv2 and why is it important in research?

SRV2 (also known as CAP) is a 600-kDa protein complex that plays a critical role in actin turnover and cytoskeletal organization. It functions through coordinated activities between its N-terminal and C-terminal halves to catalyze actin dynamics. The protein is particularly important in yeast models where it localizes to actin patch-like structures. Research interest in SRV2 stems from its fundamental role in cellular architecture and its interactions with other cytoskeletal components like cofilin (Cof1) and profilin (Pfy1) . Understanding SRV2 provides insights into basic cellular processes including morphogenesis, endocytosis, and cell division, making SRV2 antibodies valuable tools for studying these essential biological mechanisms.

What are the common applications of SRV2 antibody in research?

SRV2 antibodies are employed across multiple research applications including:

• Immunoblotting/Western blotting: To detect and quantify SRV2 protein levels in cell lysates (typically using 1:4000 dilution for anti-yeast C-Srv2 chicken polyclonal antibodies)

• Immunofluorescence microscopy: To visualize SRV2 localization and co-localization with actin and other cytoskeletal proteins

• Immunoprecipitation: To isolate SRV2 protein complexes and study protein-protein interactions

• Monitoring mutant phenotypes: To assess expression levels of mutant SRV2 proteins and correlate with phenotypic outcomes

• Validation of genetic modifications: To confirm successful integration of mutant SRV2 alleles

These applications help researchers investigate SRV2's role in actin organization, cytoskeletal dynamics, and cellular morphology.

How is SRV2 antibody specificity validated?

Validating SRV2 antibody specificity requires multiple complementary approaches:

• Genetic validation: Testing the antibody against SRV2 knockout/deletion strains (e.g., srv2Δ:: HIS3 strains) to confirm absence of signal

• Epitope mapping: Determining which specific region of the SRV2 protein the antibody recognizes (N-terminal, C-terminal, or specific domains)

• Cross-reactivity assessment: Testing against closely related proteins to ensure specificity

• Parallel detection methods: Comparing antibody detection with tagged versions of SRV2 (e.g., His₆-tagged Srv2)

• Immunoblot analysis: Confirming the antibody detects a protein of the expected molecular weight

For polyclonal antibodies, affinity purification may be necessary to reduce non-specific binding, as described in methodological approaches where SRV2 antibodies were affinity-purified prior to use in experimental procedures .

What epitope selection strategies are most effective for generating SRV2 antibodies?

Two primary strategies exist for generating effective SRV2 antibodies:

Full-Length Protein Approach:
Immunizing with purified His₆-tagged full-length Srv2 proteins expressed in E. coli BL21-RP (DE3) cells provides antibodies that recognize multiple epitopes. This approach yields antibodies capable of detecting native protein conformations but requires optimization of protein purification protocols. Expression systems typically involve growth to log phase at 37°C, followed by induction with 0.4 mM isopropyl 1-thio-β-d-galactopyranoside for 16 hours at 25°C .

Peptide-Based Approach:
Synthetic peptides corresponding to specific regions of SRV2 with known amino acid sequences can be used for immunization. This approach allows targeting of:

• Highly conserved regions

• Active sites

• Specific domains (HFD domain, coiled-coil domain)

• Regions with post-translational modifications

The primary disadvantage of the peptide approach is that selected epitopes may not be accessible in the protein's native conformation in certain assays . For optimal results, researchers should select peptides from regions that maintain accessibility in the folded protein structure.

How do different fixation methods affect SRV2 antibody performance in immunofluorescence studies?

Fixation methodology significantly impacts SRV2 antibody performance in immunofluorescence applications. Based on established protocols:

• Formaldehyde fixation (5%): Standard method used for visualization of actin organization and SRV2 co-localization in yeast cells. This approach preserves cellular architecture while maintaining epitope accessibility for most SRV2 antibodies .

• Processing protocol considerations: Special processing protocols are necessary for optimal results, as described in literature where fixed cells were processed according to established methods before probing with anti-SRV2 primary antibodies and Alexa488-phalloidin .

• Epitope masking effects: Different fixation protocols may mask specific epitopes on the SRV2 protein. Particularly, antibodies against conformational epitopes may show reduced binding after certain fixation methods that denature protein structure.

• Permeabilization optimization: When using SRV2 antibodies for co-localization studies, optimization of permeabilization agents is critical to enable antibody access to intracellular structures while preserving actin patch morphology.

The optimal approach depends on the specific SRV2 antibody being used, with polyclonal antibodies generally showing greater tolerance to fixation variability than monoclonals targeting specific epitopes.

What approaches can be used to troubleshoot non-specific binding of SRV2 antibody?

When encountering non-specific binding with SRV2 antibodies, researchers should implement the following troubleshooting strategies:

• Antibody purification: Affinity purification of SRV2 antibodies significantly reduces background. Methods for affinity purification are well-documented in literature .

• Optimized blocking protocols: Increase blocking time or test alternative blocking agents that may reduce non-specific interactions.

• Titration optimization: Systematic dilution series (e.g., 1:1000, 1:2000, 1:4000, 1:8000) to determine the minimum antibody concentration that provides specific signal.

• Cross-adsorption: Pre-incubate antibodies with lysates from SRV2-knockout strains to remove antibodies that bind to proteins other than SRV2.

• Secondary antibody controls: Include controls without primary antibody to identify non-specific binding from secondary antibodies.

• Comparison with genetic controls: Always compare staining patterns between wild-type and SRV2 mutant strains (e.g., srv2-90, srv2-91, etc.) to distinguish specific from non-specific signals .

When properly optimized, SRV2 antibodies should produce patch-like staining patterns that co-localize with actin structures, similar to patterns observed in validated immunofluorescence studies .

What controls should be included when using SRV2 antibody in experimental studies?

Rigorous experimental design with SRV2 antibodies requires several types of controls:

Essential Genetic Controls:

• Wild-type strains expressing normal levels of SRV2 (positive control)

• SRV2 deletion strains (srv2Δ:: HIS3) to confirm antibody specificity (negative control)

• Strains expressing graded levels of SRV2 or specific mutant variants (srv2-90 through srv2-94) to calibrate signal intensity

Technical Controls:

• Secondary antibody-only control to assess background staining

• Blocking peptide competition assays to confirm epitope specificity

• Dilution series to establish detection limits and linear range

Cross-validation Controls:

• Alternative detection methods (e.g., tagged SRV2 constructs)

• Independent antibody clones recognizing different SRV2 epitopes

• Correlation with functional assays (e.g., actin organization assessment)

The implementation of these controls enables confident interpretation of experimental results and differentiation between specific signal and technical artifacts.

How can researchers optimize SRV2 antibody concentrations for Western blotting?

Optimizing SRV2 antibody concentration for Western blotting requires a systematic approach:

• Initial dilution guidelines: Start with manufacturer-recommended dilutions or refer to published protocols (e.g., 1:4000 for anti-yeast C-Srv2 chicken polyclonal antibodies) .

• Titration series: Prepare a dilution series (typically 1:1000 to 1:20,000) to identify the optimal balance between specific signal and background.

• Protein loading optimization: Adjust total protein loading based on SRV2 abundance in your experimental system.

• Blocking optimization: Test different blocking agents (BSA, non-fat milk, commercial blockers) to reduce background while preserving specific signal.

• Incubation parameters: Optimize primary antibody incubation conditions:

  • Temperature (4°C, room temperature)

  • Duration (1 hour to overnight)

  • Buffer composition (PBS-T, TBS-T, with various detergent concentrations)

• Quantitative assessment: For each condition, calculate signal-to-noise ratio to determine optimal antibody concentration.

The table below illustrates a systematic optimization approach:

For quantitative Western blotting applications, validation of linearity within the selected antibody concentration is essential.

What considerations are important when storing and handling SRV2 antibody to maintain its activity?

Long-term preservation of SRV2 antibody activity requires careful attention to storage and handling conditions:

• Storage temperature:

  • Long-term: Aliquot and store at -80°C to prevent freeze-thaw damage

  • Medium-term: -20°C for periods up to 6 months

  • Working solutions: 4°C for up to 2 weeks

• Aliquoting strategy: Create single-use aliquots immediately upon receipt to minimize freeze-thaw cycles, which can cause antibody degradation and reduced specificity.

• Buffer considerations:

  • Addition of glycerol (final concentration 30-50%) for cryoprotection

  • Inclusion of carrier proteins (0.1-1% BSA) to prevent adsorption to tube walls

  • Sodium azide (0.02-0.05%) as preservative for refrigerated storage

  • pH stability (maintain pH 7.2-7.4 for optimal activity)

• Handling precautions:

  • Avoid repeated freeze-thaw cycles (limit to <5 total)

  • Centrifuge briefly after thawing to collect contents

  • Use sterile technique when handling working dilutions

  • Allow antibody to equilibrate to room temperature before opening frozen stocks

• Quality control monitoring:

  • Maintain reference samples from initial lot for comparison

  • Periodically test activity against established positive controls

  • Document performance metrics over time to identify deterioration

Proper storage and handling significantly extend the usable lifetime of SRV2 antibodies and ensure consistent experimental results.

How should researchers interpret contradictory results from different SRV2 antibody clones?

When facing contradictory results from different SRV2 antibody clones, researchers should consider:

• Epitope differences: Different antibodies may recognize distinct epitopes on SRV2 with varying accessibility in different experimental contexts. Some antibodies target the nucleocapsid region while others target spike proteins, resulting in fundamentally different detection properties .

• Cross-reactivity profiles: Evaluate each antibody for potential cross-reactivity with related proteins. Cross-validation of multiple antibodies in the same assay can help identify the most specific signal patterns.

• Assay-specific performance: Antibodies may perform differently across applications:

  • An antibody optimal for Western blotting may fail in immunoprecipitation

  • Antibodies recognizing denatured epitopes may not work in applications requiring detection of native conformations

• Resolution approach: When faced with contradictory results:

  • Generate a consensus interpretation based on multiple antibodies

  • Prioritize results from antibodies validated with genetic controls

  • Supplement antibody-based approaches with orthogonal methods

  • Consider that different antibodies may reveal different aspects of SRV2 biology

• Validation with mutant analysis: Use characterized SRV2 mutants with known phenotypes (such as srv2-90 through srv2-94) to determine which antibody results correlate best with functional outcomes .

Thoughtful integration of multiple lines of evidence provides the most reliable interpretation when antibody results appear contradictory.

What factors might contribute to variability in SRV2 antibody staining patterns?

Variability in SRV2 antibody staining patterns can arise from multiple biological and technical factors:

• Biological variables:

  • Cell cycle stage (SRV2 localization may change during cell division)

  • Cell morphology status (actin reorganization affects SRV2 distribution)

  • Genetic background differences between strains

  • Environmental stress factors that alter actin dynamics

  • Protein expression levels (natural variation or mutation-induced changes)

• Technical variables:

  • Fixation methodology (formaldehyde concentration and exposure time)

  • Permeabilization efficiency

  • Antibody penetration differences

  • Blocking effectiveness

  • Signal amplification methods

  • Microscopy settings and image acquisition parameters

• Sample-specific considerations:

  • Age of culture at harvest

  • Growth phase (log vs. stationary)

  • Nutrient conditions

  • Temperature shifts prior to fixation

• Antibody characteristics:

  • Lot-to-lot variability

  • Stability and storage conditions

  • Affinity and avidity for target epitopes

  • Non-specific binding profile

Researchers should systematically control these variables and document conditions meticulously to enable meaningful comparison between experiments.

How can researchers distinguish between specific and non-specific signals when using SRV2 antibody?

Distinguishing specific from non-specific signals requires a multi-faceted approach:

• Genetic validation: Comparison between wild-type and SRV2 deletion strains provides the gold standard for specific signal identification. Authentic signals should be absent in srv2Δ:: HIS3 strains .

• Phenotypic correlation: Antibody signals should correlate with known phenotypes. For example, in srv2-90 and srv2-91 mutants with obvious growth defects, antibody staining should reveal altered localization patterns compared to wild-type cells, while pseudo-wild-type strains (srv2-92, srv2-93, and srv2-94) should show normal localization patterns .

• Co-localization analysis: Authentic SRV2 signals should co-localize with actin patches, as confirmed by double-labeling with phalloidin .

• Signal characteristics:

  • Specific signals typically show consistent subcellular localization

  • Non-specific signals often appear as diffuse staining or random puncta

  • Specific signals demonstrate predictable changes with experimental manipulations

• Blocking peptide competition: Pre-incubation of antibody with the immunizing peptide should abolish specific signals while leaving non-specific binding intact.

• Signal-to-noise ratio assessment: Quantify the intensity ratio between areas expected to contain SRV2 versus background regions to establish threshold criteria for specific detection.

These approaches collectively provide a robust framework for distinguishing biologically meaningful signals from technical artifacts.

What is the recommended protocol for preparing yeast cell lysates for SRV2 antibody detection?

The recommended protocol for yeast cell lysate preparation optimized for SRV2 detection includes:

• Culture conditions:

  • Grow yeast to log phase at appropriate temperature

  • For temperature-sensitive strains, include both permissive and restrictive temperatures

• Cell harvesting:

  • Collect cells by centrifugation (3000×g, 5 minutes)

  • Wash once with ice-cold water

• Lysis procedure:

  • Resuspend in lysis buffer containing:

    • 50 mM phosphate buffer pH 8.0

    • 300 mM NaCl

    • 1 mM DTT

    • Protease inhibitor cocktail

  • Add glass beads to 50% of packed cell volume

  • Vortex 8 × 30 seconds with 30-second cooling intervals on ice

  • Alternative: Sonication for bacterial expression systems

• Lysate clarification:

  • Centrifuge at 16,000 rpm (SA600 rotor) for 15 minutes at 4°C

  • Transfer supernatant to fresh tube

• Protein quantification:

  • Determine protein concentration by Bradford or BCA assay

  • Normalize samples to equal protein concentration

• Sample preparation for SDS-PAGE:

  • Add Laemmli buffer to final concentration of 1×

  • Heat at 95°C for 5 minutes

This protocol ensures consistent extraction of SRV2 protein while preserving its integrity for subsequent immunoblotting analysis.

How can SRV2 antibody be used in combination with other techniques to study protein-protein interactions?

SRV2 antibody can be integrated with multiple techniques to comprehensively analyze protein-protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Use SRV2 antibody to pull down SRV2 complexes

  • Identify interaction partners by mass spectrometry or immunoblotting

  • Verify interactions bidirectionally by using antibodies against potential partners

• Proximity ligation assay (PLA):

  • Combine SRV2 antibody with antibodies against suspected interaction partners

  • Visualize interactions as fluorescent spots when proteins are within 40 nm

  • Quantify interaction frequency and subcellular localization

• Bimolecular fluorescence complementation (BiFC):

  • Validate interactions identified by antibody-based methods

  • Correlate antibody staining patterns with BiFC signal distribution

• Functional assays with mutant analysis:

  • Use SRV2 antibody to confirm expression of mutant proteins

  • Correlate protein interaction changes with phenotypic outcomes

  • Example: srv2-90 and srv2-91 alleles showed growth defects at 37°C, while srv2-92, srv2-93, and srv2-94 showed normal growth

• Correlative microscopy:

  • Combine immunofluorescence using SRV2 antibody with electron microscopy

  • Map protein interactions to specific cellular ultrastructures

• In vitro reconstitution:

  • Use purified components to reconstruct interactions

  • Verify with SRV2 antibody detection

This multi-method approach provides complementary lines of evidence about SRV2's interaction network and functional partnerships.

What are common issues encountered with SRV2 antibody in Western blotting and their solutions?

Common Western blotting issues with SRV2 antibody and their solutions include:

When troubleshooting, systematically modify one variable at a time and document all changes to identify the optimal conditions for your experimental system.

How should researchers validate newly acquired SRV2 antibody lots?

Comprehensive validation of new SRV2 antibody lots should include:

• Specificity testing:

  • Western blot comparison between wild-type and SRV2 knockout strains

  • Peptide competition assay to confirm epitope specificity

  • Immunofluorescence pattern correlation with expected SRV2 localization (patch-like structures co-localizing with actin)

• Performance benchmarking:

  • Side-by-side comparison with previous lot

  • Titration series to determine optimal working dilution

  • Sensitivity assessment using serial dilutions of positive control samples

• Cross-application testing:

  • Validate across all intended applications (Western blot, immunofluorescence, immunoprecipitation)

  • Different applications may require different optimal concentrations

• Reproducibility assessment:

  • Technical replicates to measure consistency

  • Testing by multiple users if possible

  • Evaluation across different experimental conditions

• Documentation requirements:

  • Record lot number, dilution factor, and incubation conditions

  • Capture representative images of validation results

  • Create standardized protocols for each application

This systematic validation approach ensures consistent performance across antibody lots and minimizes experimental variability.

How can SRV2 antibody be used to study the relationship between actin dynamics and cellular morphology?

SRV2 antibody enables sophisticated analysis of actin-morphology relationships through several approaches:

• Co-localization studies:

  • Double-labeling with SRV2 antibody and actin markers (Alexa488-phalloidin)

  • Quantitative co-localization analysis to measure spatial correlation

  • Time-course experiments to track dynamic changes

• Mutant phenotype analysis:

  • Compare SRV2 localization and actin organization across mutant alleles

  • Correlate antibody staining patterns with morphological phenotypes

  • Example: srv2-90 and srv2-91 mutants showed abnormally large and rounded morphologies with diminished actin cable staining and depolarization of actin patches, while pseudo-wild-type alleles maintained normal morphology and actin organization

• Genetic interaction studies:

  • Examine SRV2 localization in genetic backgrounds with mutations in actin regulators

  • Use synthetic lethal interactions (e.g., with pfy1-4 and cof1-19) to identify functional relationships

• Functional domain mapping:

  • Use antibodies against specific SRV2 domains to determine which regions contribute to actin organization

  • Correlate domain function with morphological outcomes

• Quantitative morphometry:

  • Measure cell dimensions, actin patch polarization, and SRV2 distribution parameters

  • Perform statistical analysis to identify significant correlations

This multi-faceted approach provides mechanistic insights into how SRV2's interaction with the actin cytoskeleton influences cellular architecture and morphogenesis.

What considerations are important when designing SRV2 epitope-specific antibodies for specialized applications?

Designing epitope-specific SRV2 antibodies requires careful consideration of structure-function relationships:

• Domain-specific targeting:

  • N-terminal region: Contains coiled-coil domain important for oligomerization

  • C-terminal region: Contains actin-binding and regulatory domains

  • Hexapeptide folding domain (HFD): Critical for structural integrity

• Functional epitope selection:

  • Target conserved regions for evolutionary studies

  • Focus on interaction interfaces to study protein partnerships

  • Select surface-exposed residues for accessibility in native protein

  • Consider targeting regions with known functional mutations (e.g., residues mutated in srv2-90 through srv2-94)

• Peptide design principles:

  • Optimal length: 10-20 amino acids

  • Avoid hydrophobic stretches that may cause solubility issues

  • Include unique sequence regions to prevent cross-reactivity

  • Consider adding terminal cysteine for conjugation chemistry if not naturally present

• Application-specific considerations:

  • For immunofluorescence: Select epitopes accessible in fixed cells

  • For immunoprecipitation: Target epitopes outside of protein interaction domains

  • For detecting conformational changes: Design antibodies recognizing specific structural states

• Production strategy selection:

  • Monoclonal: Higher specificity, consistent performance, epitope-specific

  • Polyclonal: Multiple epitope recognition, higher sensitivity, more robust to fixation

Thoughtful epitope selection based on SRV2's structure and function significantly enhances antibody utility in specialized research applications.

How are SRV2 antibodies contributing to our understanding of cytoskeletal dynamics in disease models?

SRV2 antibodies are enabling new insights into cytoskeletal dynamics in disease contexts:

• Neurodegenerative disease models:

  • Analysis of actin-binding protein interactions in neuronal development

  • Investigation of cytoskeletal abnormalities in neurodegenerative processes

  • Correlation between SRV2 function and neuronal morphology maintenance

• Cancer cell models:

  • Examination of cytoskeletal reorganization during metastatic transformation

  • Study of SRV2's role in cancer cell migration and invasion

  • Potential therapeutic targeting of actin regulatory pathways

• Cardiovascular disease research:

  • Analysis of cytoskeletal integrity in cardiomyocytes

  • Investigation of mechanotransduction pathways in disease progression

  • Correlation between SRV2 function and cellular responses to mechanical stress

• Genetic disorder studies:

  • Characterization of cytoskeletal defects in genetic conditions affecting actin dynamics

  • Functional analysis of disease-associated mutations in SRV2 or interacting partners

  • Development of screening approaches for cytoskeletal dysfunction

SRV2 antibodies provide essential tools for investigating how alterations in cytoskeletal regulation contribute to disease pathogenesis and for identifying potential therapeutic targets within these pathways.

What methodological advances are enhancing the utility of SRV2 antibodies in quantitative cell biology?

Recent methodological advances are expanding SRV2 antibody applications in quantitative cell biology:

• Super-resolution microscopy integration:

  • STORM/PALM techniques allow nanoscale visualization of SRV2 organization

  • SIM provides enhanced resolution of SRV2-actin co-localization

  • Quantitative analysis of SRV2 distribution at previously unresolvable scales

• Live-cell imaging approaches:

  • Development of membrane-permeable SRV2 antibody fragments

  • Complementary approaches using fluorescent protein fusions to validate antibody findings

  • Correlation between fixed-cell immunofluorescence and live-cell dynamics

• High-content screening applications:

  • Automated image analysis workflows for SRV2 immunofluorescence

  • Machine learning algorithms for pattern recognition and phenotype classification

  • Large-scale screening of genetic or chemical perturbations affecting SRV2 function

• Multiplexed detection systems:

  • Simultaneous visualization of multiple cytoskeletal components with SRV2

  • Mass cytometry approaches for high-dimensional protein interaction analysis

  • Spatial proteomics to map SRV2 within subcellular compartments

• Quantitative Western blotting advances:

  • Fluorescent secondary antibodies for precise quantification

  • Automated analysis software for standardized measurement

  • Internal loading controls for more accurate normalization

These methodological advances are transforming SRV2 antibody applications from qualitative observations to precise quantitative measurements, enabling deeper insights into cytoskeletal biology.